GranuFlo Lawsuits Mount, as Bernstein Liebhard LLP Notes New Consolidated Litigation for GranuFlo Recall Claims Filed in Massachusetts State Court

• 

Consolidated proceedings such as this, as well as the multidistrict litigation already underway in Massachusetts Federal Court, will allow what could be a large number of GranuFlo lawsuit filings to proceed more efficiently through the court system.

New York, New York (PRWEB) September 10, 2013

GranuFlo lawsuit (http://www.granuflodialysislawsuits.com/) claims filed in the wake of last year’s recall of Fresenius Medical Care’s GranuFlo and NaturaLyte dialysis drugs continue to mount in state and federal courts around the country, Bernstein Liebhard LLP reports. According to an Order issued on September 3, 2013, all pending and future GranuFlo recall claims filed in Massachusetts State Court have been consolidated in Middlesex County (Mass.) Superior Court before Judge Maynard M. Kirpalani. Judge Kirpalani has scheduled a Status Conference for September 17th at 2:00 p.m. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O)

“Prior to the GranuFlo recall, GranuFlo and NaturaLyte were used by thousands of dialysis clinics in the U.S. Consolidated proceedings such as this, as well as the multidistrict litigation already underway in Massachusetts Federal Court, will allow what could be a large number of GranuFlo lawsuit filings to proceed more efficiently through the court system,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other heart side effects allegedly related to the GranuFlo recall.

GranuFlo Recall
GranuFlo and NaturaLyte were widely used at Fresenius Medical Care’s own dialysis clinics, and were also used to treat an estimated 125,000 patients at clinics outside of the Fresenius network. Both were the subject of an “Urgent Product Notification” Fresenius issued to its customer clinics in March of 2012 that warned of possible heart risks associated with the products. Several months later, the U.S. Food & Drug Administration (FDA) deemed the notification a Class I GranuFlo recall, a designation that is only granted when a medical product poses a significant risk of serious injury or death.

According to a New York Times report published in June 2012, the FDA launched an investigation of Fresenius Medical Care shortly after the GranuFlo recall was announced, after learning that the company had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. Among other things, the agency advised doctors to adjust their dosage to avoid these dangers.*

Since the announcement of the GranuFlo recall, court records indicate that hundreds of plaintiffs
have filed lawsuits against Fresenius Medical Care that claim the company failed to provide adequate warnings regarding the use of the products, and assert that the company continued to aggressively market GranuFlo and NaturaLyte even after the company became aware of their dangers. In addition to the newly-established litigation in Massachusetts State Court, at least 300 federally-filed GranuFlo lawsuits are pending in a multidistrict litigation now underway in U.S. District Court, District of Massachusetts. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428) According to the Order issued on September 3rd in Middlesex County Superior Court, Judge Kirpalani has directed the parties in the state proceeding to coordinate with the federal multidistrict litigation.

Dialysis patients who suffered sudden and serious heart problems within 72 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to compensation for medical bills, lost wages and other damages. Learn More about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.granuflodialysislawsuits.com/

PDF Print